Biocon biosimilars launches and capacity ramp offset Syngene research services weakness

Investment View and Key Thesis

Motilal Oswal Financial Services Limited retained its Buy recommendation on Biocon in its August 6, 2026 results update. The central thesis is that robust growth in biosimilars and generics can offset near-term weakness in Syngene's research-services business.

The broker expects biosimilars and generics to improve over the near to medium term through new product launches and better utilisation of manufacturing capacity. In contrast, recovery in the research-services business is likely to require more time.

1QFY27 Financial Performance

Biocon reported consolidated revenue of Rs 43.4 billion in 1QFY27, representing 10 per cent year-on-year growth, but 5 per cent below Motilal Oswal's estimate of Rs 45.9 billion. Gross margin expanded by 150 basis points year-on-year to 63.1 per cent, supported by product mix. However, EBITDA margin was flat year-on-year at 19.5 per cent, below the broker's 21.9 per cent estimate, as other expenses increased by 90 basis points as a share of sales and R&D costs rose by 30 basis points.

Adjusted PAT excludes a Rs 130 million exceptional employee-termination expense. The year-on-year increase in adjusted PAT was primarily driven by a tax benefit. In the quarter, biosimilars represented 66 per cent of revenue, while generics and research services each contributed 17 per cent.

Biosimilars: Primary Earnings Driver

Biosimilars drove the quarter's earnings. Excluding Syngene, Biocon's biologics EBITDA was Rs 7.3 billion, with a 25 per cent margin and 10 per cent year-on-year growth. The biosimilars business benefited from increased North American sales and new launches.

Management expects segment growth to accelerate in 2HFY27, led by Aflibercept, Denosumab, Ustekinumab, Bevacizumab and insulins across key markets. Approval of the second product line at the Malaysian facility is expected to ease manufacturing constraints and support scaling.

Management reiterated its plan to launch at least one new biosimilar annually in the US and Europe. Legacy products, including Fulphila, Trastuzumab, Insulin Glargine and Adalimumab, continue to deliver durable market share and margins.

Generics Growth and Margin Outlook

Generics profitability is improving through higher sales, including Liraglutide in multiple markets, and cost-efficiency measures. Management expects the generics EBITDA margin to expand in FY27 on the back of new launches.

Biocon is prioritising profitable growth over aggressive market-share gains. It is also evaluating local US partnerships for commercialisation and does not plan to undertake incremental US manufacturing capex.

Syngene Research-Services Weakness

Syngene was the key drag on performance. Its 1QFY27 revenue declined 16 per cent year-on-year to Rs 7.4 billion, owing to lower offtake from a key biologics customer. EBITDA margin contracted by 1,130 basis points year-on-year to 23.6 per cent.

Management described FY27 as a transition year and expects improvement in 2HFY27. It targets a return to sustainable profitable growth from FY28, supported by stronger commercial execution, operating efficiency, new customers and deeper business with existing customers.

Syngene is expected to report a single-digit revenue decline in FY27. Motilal Oswal forecasts a 3.4 per cent revenue CAGR decline over FY26-FY28, with revenue reaching Rs 34.9 billion.

Estimates and Valuation

Motilal Oswal cut its FY27 and FY28 earnings estimates by 12 per cent and 3 per cent, respectively. The revisions reflect the weak research-services outlook, commercial-execution initiatives and optimised R&D spending.

The target price of Rs 520 is based on a sum-of-the-parts valuation. The valuation applies 22 times EV/EBITDA to biosimilars, 10 times EV/EBITDA to generics and a 15 per cent holding-company discount to Biocon's stake in Syngene.

Key Risks and Operating Considerations

• Sustained weak customer offtake and a delayed recovery at Syngene.
• Capacity constraints in biosimilars.
• Execution risks related to product launches and commercial expansion.

Net debt increased during the quarter because of inventory-led working-capital needs. Management expects working capital to normalise by year-end.